Cargando…
Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study
BACKGROUND: Atrial fibrillation (AF) is a common arrhythmia in patients with hypertension. ELABELA, which has cardioprotective effects, is decreased in the plasma of patients with hypertension and might be associated with AF in the hypertensive population. This study aims to measure the ELABELA plas...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359615/ https://www.ncbi.nlm.nih.gov/pubmed/34384364 http://dx.doi.org/10.1186/s12872-021-02197-x |
_version_ | 1783737584535470080 |
---|---|
author | Ma, Zheng Zhao, Lei Zhang, Ye-ping Zhong, Jiu-chang Yang, Xin-chun |
author_facet | Ma, Zheng Zhao, Lei Zhang, Ye-ping Zhong, Jiu-chang Yang, Xin-chun |
author_sort | Ma, Zheng |
collection | PubMed |
description | BACKGROUND: Atrial fibrillation (AF) is a common arrhythmia in patients with hypertension. ELABELA, which has cardioprotective effects, is decreased in the plasma of patients with hypertension and might be associated with AF in the hypertensive population. This study aims to measure the ELABELA plasma levels in hypertension patients with and without AF and to analyse the related factors. METHODS: A total of 162 hypertension patients with or without AF were recruited for our monocentric observational study. Subjects were excluded if they had a history of valvular heart disease, rheumatic heart disease, cardiomyopathy, thyroid diseases, or heart failure. The patients’ histories were recorded, and laboratory examinations were conducted. Plasma ELABELA was detected by immunoassay. Echocardiographs were performed, and parameters were collected by two experienced doctors. Binary logistic regression analysis was used to identify the association between ELABELA plasma level and AF in patients with hypertension. RESULTS: Plasma ELABELA levels were lower in hypertension patients with AF than in those without AF (2.0 [1.5, 2.8] vs. 4.0 [3.4, 5.0] ng/ml, P < 0.001). ELABELA levels were correlated with age, heart rate, BNP levels and left atrial dimension. In addition to the left atrial dimension, ELABELA plasma levels were associated with AF in patients with hypertension (OR 0.081, 95% CI 0.029–0.224, P < 0.001). ELABELA levels were further decreased in the persistent AF subgroup compared with the paroxysmal AF subgroup (1.8 [1.4, 2.5] vs. 2.2 [1.8, 3.0] ng/ml, P = 0.012) and correlated with HR, BNP and ESR levels. CONCLUSIONS: ELALABELA levels were decreased in hypertension patients with AF and further lowered in the persistent AF subgroup. Decreased ELABELA plasma levels were associated with AF in hypertension patients and may be an underlying risk factor. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-021-02197-x. |
format | Online Article Text |
id | pubmed-8359615 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83596152021-08-16 Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study Ma, Zheng Zhao, Lei Zhang, Ye-ping Zhong, Jiu-chang Yang, Xin-chun BMC Cardiovasc Disord Research Article BACKGROUND: Atrial fibrillation (AF) is a common arrhythmia in patients with hypertension. ELABELA, which has cardioprotective effects, is decreased in the plasma of patients with hypertension and might be associated with AF in the hypertensive population. This study aims to measure the ELABELA plasma levels in hypertension patients with and without AF and to analyse the related factors. METHODS: A total of 162 hypertension patients with or without AF were recruited for our monocentric observational study. Subjects were excluded if they had a history of valvular heart disease, rheumatic heart disease, cardiomyopathy, thyroid diseases, or heart failure. The patients’ histories were recorded, and laboratory examinations were conducted. Plasma ELABELA was detected by immunoassay. Echocardiographs were performed, and parameters were collected by two experienced doctors. Binary logistic regression analysis was used to identify the association between ELABELA plasma level and AF in patients with hypertension. RESULTS: Plasma ELABELA levels were lower in hypertension patients with AF than in those without AF (2.0 [1.5, 2.8] vs. 4.0 [3.4, 5.0] ng/ml, P < 0.001). ELABELA levels were correlated with age, heart rate, BNP levels and left atrial dimension. In addition to the left atrial dimension, ELABELA plasma levels were associated with AF in patients with hypertension (OR 0.081, 95% CI 0.029–0.224, P < 0.001). ELABELA levels were further decreased in the persistent AF subgroup compared with the paroxysmal AF subgroup (1.8 [1.4, 2.5] vs. 2.2 [1.8, 3.0] ng/ml, P = 0.012) and correlated with HR, BNP and ESR levels. CONCLUSIONS: ELALABELA levels were decreased in hypertension patients with AF and further lowered in the persistent AF subgroup. Decreased ELABELA plasma levels were associated with AF in hypertension patients and may be an underlying risk factor. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-021-02197-x. BioMed Central 2021-08-12 /pmc/articles/PMC8359615/ /pubmed/34384364 http://dx.doi.org/10.1186/s12872-021-02197-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Ma, Zheng Zhao, Lei Zhang, Ye-ping Zhong, Jiu-chang Yang, Xin-chun Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study |
title | Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study |
title_full | Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study |
title_fullStr | Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study |
title_full_unstemmed | Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study |
title_short | Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study |
title_sort | declined elabela plasma levels in hypertension patients with atrial fibrillation: a case control study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359615/ https://www.ncbi.nlm.nih.gov/pubmed/34384364 http://dx.doi.org/10.1186/s12872-021-02197-x |
work_keys_str_mv | AT mazheng declinedelabelaplasmalevelsinhypertensionpatientswithatrialfibrillationacasecontrolstudy AT zhaolei declinedelabelaplasmalevelsinhypertensionpatientswithatrialfibrillationacasecontrolstudy AT zhangyeping declinedelabelaplasmalevelsinhypertensionpatientswithatrialfibrillationacasecontrolstudy AT zhongjiuchang declinedelabelaplasmalevelsinhypertensionpatientswithatrialfibrillationacasecontrolstudy AT yangxinchun declinedelabelaplasmalevelsinhypertensionpatientswithatrialfibrillationacasecontrolstudy |